Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
<h4>Background</h4>Bone loss, in malignant or non-malignant diseases, is caused by increased osteoclast resorption and/or reduced osteoblast bone formation, and is commonly associated with skeletal complications. Thus, there is a need to identify new agents capable of influencing bone re...
Guardado en:
Autores principales: | Antonio Garcia-Gomez, Enrique M Ocio, Edvan Crusoe, Carlos Santamaria, Pilar Hernández-Campo, Juan F Blanco, Fermin M Sanchez-Guijo, Teresa Hernández-Iglesias, Jesús G Briñón, Rosa M Fisac-Herrero, Francis Y Lee, Atanasio Pandiella, Jesús F San Miguel, Mercedes Garayoa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b5156085cd814cbb9ad781f61ac1696e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis
por: Robert D. Little, et al.
Publicado: (2017) -
Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
por: Rhodora C. Calizo, et al.
Publicado: (2019) -
Women's Experiences of Using Anabolic Androgenic Steroids
por: Annica Börjesson, et al.
Publicado: (2021) -
Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Zakaria Maat, et al.
Publicado: (2021) -
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Radhakrishnan Ramchandren, et al.
Publicado: (2009)